Line 166: |
Line 166: |
| ===Histamine 2 receptor antagonists=== | | ===Histamine 2 receptor antagonists=== |
| | | |
− | This concept follows from the still widely held belief, ‘no acid, no ulcer’ (Fig 19). The current treatment of choice is to suppress acid production from the parietal cells. These cells release acid when any one of 3 distinct receptors (histamine, acetylcholine, gastrin) is stimulated. Currently, the most popular treatment involves an histamine receptor antagonist (H2 blocker). The proton-pump inhibitors constitute a new treatment approach that blocks acid production within the cell. This modality is receptor-independent and therefore more effective.(EGUC)
| + | Parietal cells secrete HCl upon stimulation of histamine, acetylcholine or gastrin receptors.(EGUC) Competitive H2 receptor antagonists have successfully elevated gastric pH and treated gastric ulcers in mature horses and foals.(44,85,97 in Sachez) |
− | Histamine receptor (H2) antagonists
| + | |
− | The 4 most popular Hz antagonists licensed in the United States for man are cimetidine, ranitidine, famotidine and nizatidine. Cimetidine has been shown to affect hepatic disposition of some drugs.
| + | Currently recommended doses proposed to be effective in the majority of horses(Sanchez) are: |
− | Most of these compounds have been tested in the horse; cimetidine and ranitidine have been studied most extensively (Table 2). Ranitidine at a dose of 6.6 mgkg bwt q. 8 h has been demonstrated to maintain a pH level >4 when horses are allowed free access to hay.(EGUC)
| + | *'''Cimetidine''' 20-30mg/kg PO every 8 hours or 6.6mg/kg IV every 6 hours |
− | Horses with documented gastric ulcers respond well to treatment with histamine type-2 receptor (Hz) antagonists such as ranitidine (Furr and Murray 1989; Murray and Grodinsky 1992).
| + | *'''Ranitidine''' 6.6mg/kg PO every 8 hours or 1.5-2mg/kg IV every 6 hours |
− | The problem with treatment of gastric ulcers in horses is that individuals have different dose requirements for effective treatment. This probably relates to varying bioavailability of the drug in individual horses. The bioavailability of H2 antagonists is generally lower in horses than in man. The wide variability among horses in acid suppression achieved with H2 antagonists may be a result of other unknown factors as well; this variability is most pronounced at low doses. The medication selected, dosage and duration of treatment depend on the location and severity of lesions, clinical signs, and owner considerations., | + | *'''Famotidine''' 10-15mg/kg PO every 24 hours |
− | The recommended dose of oral ranitidine is 6.6 mg/kg bwt 3 times daily. The equivalent dose of cimetidine is 40-60 mg/kg/day; and of famotidine 10 mg/kg/day. Treatment is effective and alleviates clinical signs in those that are affected. Lower dosages may be effective in some horses, but the percentage of individuals that fail to respond increases as the dosage decreases.(Orsini)
| + | |
| + | The proton-pump inhibitors constitute a new treatment approach that blocks acid production within the cell. This modality is receptor-independent and therefore more effective.(EGUC) |
| + | |
| + | |
| + | Cimetidine has been shown to affect hepatic disposition of some drugs. |
| + | |
| + | The problem with treatment of gastric ulcers in horses is that individuals have different dose requirements for effective treatment. This probably relates to varying bioavailability of the drug in individual horses. The wide variability among horses in acid suppression achieved with H2 antagonists |
| | | |
| ===Proton-pump inhibitors=== | | ===Proton-pump inhibitors=== |